Pedro Duarte Gaburri

Pedro Duarte Gaburri

Auto-generated profile, based on publicly available information

Pedro Duarte Gaburri

Universidade Federal de Juiz de Fora, Brasil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
JRJosé E.R. Ricci
José E.R. Ricci
LCLiliana A. Chebli
Liliana A. Chebli
TRTarsila C.D.R. Ribeiro
Tarsila C.D.R. Ribeiro
ACAntonio C.S. Castro
Antonio C.S. Castro
PGPedro D. Gaburri
Pedro D. Gaburri
JCJúlio Maria Chebli
Júlio Maria Chebli
Goals: We studied the prevalence and predictors of small-intestinal bacterial overgrowth (SIBO) in Crohn’s disease (CD) outpatients and the relationship between SIBO and intestinal and/or systemic inflammation. Background: The relationship of SIBO with systemic and intestinal inflammation in CD patients is unclear. Study: In this cross-sectional study, conducted between June, 2013 and January, 2015, 92 CD patients and 97 controls with nonchronic gastrointestinal complaints were assessed for the presence of SIBO using the H2/CH4 glucose breath test. Multivariate logistic regression was performed to investigate the potential association between SIBO and demographic, disease-related data, systemic markers of inflammation (C-reactive protein, and erythrocyte sedimentation rate), and biomarker of intestinal inflammation [fecal calprotectin concentration (FCC)]. Results: The SIBO rate was significantly higher in CD patients than in controls (32.6% vs. 12.4%, respectively, P=0.0008). Patients with and without SIBO were comparable with regard to demographics, systemic inflammatory biomarkers, and disease characteristics, except for the stricturing phenotype being more common in SIBO-positive CD patients (43.3% vs. 19.3%, P=0.015). Notably, FCC was significantly higher in SIBO-positive patients (median of 485.8 vs.132.7 μg/g; P=0.004). Patients presenting increased FCC and stricturing disease had an odds of 9.43 (95% confidence interval, 3.04-11.31; P<0.0001) and 3.83 (95% confidence interval, 1.54-6.75; P=0.025) respectively, for SIBO diagnosis. Conclusions: In CD patients, SIBO is a highly prevalent condition. Stricturing phenotype and increased FCC were strongly and independently associated with the presence of SIBO. SIBO diagnostic work-up followed by directed treatment is recommended in CD patients who present stricturing disease, especially in those with concurrent intestinal inflammation.

1 March 2022 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
FFFernanda Cristina Zimmermann Franco
Fernanda Cristina Zimmermann Franco
MOMirella Chrispim Cerqueira de Oliveira
Mirella Chrispim Cerqueira de Oliveira
PGPedro Duarte Gaburri
Pedro Duarte Gaburri
DFDanielle Cristina Zimmermann Franco
Danielle Cristina Zimmermann Franco
JCJúlio Maria Chebli
Júlio Maria Chebli
Background Ulcerative colitis (UC) is a chronic inflammatory disease whose manifestations can drastically affect the individual’s quality of life, and therefore adherence to treatment is important in order to keep it in remission. Objective To verify the prevalence of non-adherence and the influence of sociodemographic, clinical and pharmacotherapeutic characteristics associated with non-adherence to treatment of UC in remission. Methods Cross-sectional study conducted with 90 individuals diagnosed with UC in remission. The information was collected through interviews during medical consultations at Medical Clinic of Gastroenterology of Hospital Universitário da Universidade Federal de Juiz de Fora. To verify the association of the variables under study with the outcome of interest and its measure of association, Student’s t-test or Pearson’s chi-square non-parametric test (P<0.05) was used and prevalence ratio and confidence interval were calculated. Results A high prevalence of non-adherence (77.8%) was found among patients with UC in remission. The individuals most likely to not adhere to the treatment were those aged less than 50 years, who were not engaged in paid work, with high scores for anxiety and who used more than one medication as part of the treatment of UC. Conclusion These findings reinforce that acknowledging the factors that influence the non-adherence behavior is of paramount importance for the development of strategies by health care professionals, assuring that those will be really effective to prolong, as much as possible, one of the most successful ways to maintain the UC remission period: the use of medications.

1 November 2020 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
FLFernando de Azevedo Lucca
Fernando de Azevedo Lucca
CMCarla Malaguti
Carla Malaguti
LCLiliana Andrade Chebli
Liliana Andrade Chebli
MRMaycon Moura Reboredo
Maycon Moura Reboredo
BPBruno Valle Pinheiro
Bruno Valle Pinheiro
JCJúlio Maria Chebli
Júlio Maria Chebli
SUMMARY AIM: To compare the level of physical activity (PA), exercise capacity, and body composition before and after infliximab-induced clinical remission in patients with Crohn's disease (CD). METHODS: This prospective longitudinal study evaluated 44 adult outpatients with active CD before infliximab administration and 24 weeks after infliximab therapy. The patients were evaluated for PA in daily life, exercise capacity, muscle strength, and body composition. RESULTS: 38 (86.4%) patients achieved infliximab-induced remission at 24 weeks and presented an increment in the number of steps taken of 1092 (7440±2980 vs. 6348±3177, respectively; p=0.006). The inactive time was reduced when compared to the baseline value (454.2±106.3 vs. 427.9±97.8, respectively; p=0.033). There was no difference in the distance walked before and after infliximab therapy, while there was an increase in the fat mass index in responders to infliximab compared to the baseline (19.1±7.6 vs. 14.9±5.8; p=0.001). CONCLUSIONS: Infliximab-induced remission was shown to be effective for increasing physical activity by improving the number of steps and reducing inactive time. The maintenance of clinical remission associated with incentives to regular PA may contribute to making these patients reach an ideal level of PA.